PD1 and TIM3 Expression is Associated with Very Early Hepatocellular Carcinoma Recurrence After Percutaneous Thermal Ablation

References

• Wang H, Wu Z, Cui D, Shi Y, Zhai B. Radiofrequency ablation of hepatocellular carcinoma: current status, challenges, and prospects. Liver Res. 2023;7(2):108–115. doi:10.1016/j.livres.2023.05.002
   Google Scholar
• Dong TT, Wang L, Li M, Yin C, Li YY, Nie F. Clinical Results, Risk Factors, and Future Directions of Ultrasound-Guided Percutaneous Microwave Ablation for Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2023;10:733–743. doi:10.2147/jhc.S409011
   PubMed Web of Science ®Google Scholar
• Huber TC, Bochnakova T, Koethe Y, Park B, Farsad K. Percutaneous Therapies for Hepatocellular Carcinoma: evolution of Liver Directed Therapies. J Hepatocell Carcinoma. 2021;8:1181–1193. doi:10.2147/jhc.S268300
   PubMed Web of Science ®Google Scholar
• Galle PR. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.019
   PubMed Web of Science ®Google Scholar
• Nault JC, Sutter O, Nahon P, Ganne-Carrie N, Seror O. Percutaneous treatment of hepatocellular carcinoma: state of the art and innovations. J Hepatol. 2018;68(4):783–797. doi:10.1016/j.jhep.2017.10.004
   PubMed Web of Science ®Google Scholar
• Livraghi T, Meloni F, Di Stasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology. 2008;47(1):82–89. doi:10.1002/hep.21933
   PubMed Web of Science ®Google Scholar
• N’Kontchou G, Mahamoudi A, Aout M, et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology. 2009;50(5):1475–1483. doi:10.1002/hep.23181
   PubMed Web of Science ®Google Scholar
• Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38(2):200–207. doi:10.1016/s0168-8278(02)00360-4
   PubMed Web of Science ®Google Scholar
• Hermida M, Cassinotto C, Piron L, et al. Multimodal Percutaneous Thermal Ablation of Small Hepatocellular Carcinoma: predictive Factors of Recurrence and Survival in Western Patients. Cancers. 2020;12(2):313. doi:10.3390/cancers12020313
   PubMed Web of Science ®Google Scholar
• Preel A, Hermida M, Allimant C, et al. Uni-, Bi- or Trifocal Hepatocellular Carcinoma in Western Patients: recurrence and Survival after Percutaneous Thermal Ablation. Cancers. 2021;13(11):2700. doi:10.3390/cancers13112700
   PubMed Web of Science ®Google Scholar
• Versluis JM, Long GV, Blank CU. Learning from clinical trials of neoadjuvant checkpoint blockade. Nature Med. 2020;26(4):475–484. doi:10.1038/s41591-020-0829-0
   PubMed Web of Science ®Google Scholar
• Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, Phase 3 trial. Lancet Oncol. 2021;23(1):77–90. doi:10.1016/s1470-2045(21)00604-5
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Macek Jilkova Z, Ghelfi J, Decaens T. Immunomodulation for hepatocellular carcinoma therapy: current challenges. Current Opinion Oncol. 2022;34(2):155–160. doi:10.1097/cco.0000000000000812
   PubMed Web of Science ®Google Scholar
• Ji JH, Ha SY, Lee D, et al. Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma. Int J Mol Sci. 2023;24(8):7640. doi:10.3390/ijms24087640
   PubMed Web of Science ®Google Scholar
• Macek Jilkova Z, Aspord C, Decaens T. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: current Status and Challenges. Cancers. 2019;11(10):1554. doi:10.3390/cancers11101554
   PubMed Web of Science ®Google Scholar
• Tischfield DJ, Gurevich A, Johnson O, et al. Transarterial Embolization Modulates the Immune Response within Target and Nontarget Hepatocellular Carcinomas in a Rat Model. Radiology. 2022:211028. doi:10.1148/radiol.211028
   Google Scholar
• Zhu J, Yu M, Chen L, et al. Enhanced antitumor efficacy through microwave ablation in combination with immune checkpoints blockade in breast cancer: a pre-clinical study in a murine model. Diagn Interventional Imaging. 2018;99(3):135–142. doi:10.1016/j.diii.2017.12.011
   PubMed Web of Science ®Google Scholar
• Dumolard L, Ghelfi J, Roth G, Decaens T, Macek Jilkova Z. Percutaneous Ablation-Induced Immunomodulation in Hepatocellular Carcinoma. Int J Mol Sci. 2020;21(12):4398. doi:10.3390/ijms21124398
   PubMed Web of Science ®Google Scholar
• Takaki H, Cornelis F, Kako Y, Kobayashi K, Kamikonya N, Yamakado K. Thermal ablation and immunomodulation: from preclinical experiments to clinical trials. Diagn Interventional Imaging. 2017;98(9):651–659. doi:10.1016/j.diii.2017.04.008
   PubMed Web of Science ®Google Scholar
• Li L, Wang W, Pan H, et al. Microwave ablation combined with OK-432 induces Th1-type response and specific antitumor immunity in a murine model of breast cancer. J Transl Med. 2017;15(1):23. doi:10.1186/s12967-017-1124-9
   PubMed Web of Science ®Google Scholar
• Huang KW, Jayant K, Lee PH, et al. Positive Immuno-Modulation Following Radiofrequency Assisted Liver Resection in Hepatocellular Carcinoma. J Clin Med. 2019;8(3):385. doi:10.3390/jcm8030385
   PubMed Web of Science ®Google Scholar
• Hiam-Galvez KJ, Allen BM, Spitzer MH. Systemic immunity in cancer. Nat Rev Cancer. 2021;21(6):345–359. doi:10.1038/s41568-021-00347-z
   PubMed Web of Science ®Google Scholar
• Macek Jilkova Z, Aspord C, Kurma K, et al. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment. Clin Transl Gastroenterol. 2019;10(7):e00058. doi:10.14309/ctg.0000000000000058
   PubMedGoogle Scholar
• Li Z, Zheng B, Qiu X, et al. The identification and functional analysis of CD8+PD-1+CD161+ T cells in hepatocellular carcinoma. Npj Precision Oncology. 2020;4(1):28. doi:10.1038/s41698-020-00133-4
   PubMed Web of Science ®Google Scholar
• Liu F, Liu Y, Chen Z. Tim-3 expression and its role in hepatocellular carcinoma. J Hematol Oncol. 2018;11(1):126. doi:10.1186/s13045-018-0667-4
   PubMedGoogle Scholar
• Tay RE, Richardson EK, Toh HC. Revisiting the role of CD4(+) T cells in cancer immunotherapy-new insights into old paradigms. Cancer Genet Ther. 2021;28(1–2):5–17. doi:10.1038/s41417-020-0183-x
   PubMed Web of Science ®Google Scholar
• Erinjeri JP, Fine GC, Adema GJ, et al. Immunotherapy and the Interventional Oncologist: challenges and Opportunities-A Society of Interventional Oncology White Paper. Radiology. 2019;292(1):25–34. doi:10.1148/radiol.2019182326
   PubMed Web of Science ®Google Scholar
• Wang K, Wang C, Jiang H, et al. Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: where We Are and Where to Go. Front Immunol. 2021;12:792781. doi:10.3389/fimmu.2021.792781
   PubMed Web of Science ®Google Scholar
• Qin S, Chen M, Cheng AL, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402(10415):1835–1847. doi:10.1016/s0140-6736(23)01796-8
   PubMed Web of Science ®Google Scholar
• Kurebayashi Y, Ojima H, Tsujikawa H, et al. Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification. Hepatology. 2018;68(3):1025–1041. doi:10.1002/hep.29904
   PubMed Web of Science ®Google Scholar
• Agdashian D, ElGindi M, Xie C, et al. The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma. Cancer Immunol Immunother. 2019;68(4):599–608. doi:10.1007/s00262-019-02299-8
   PubMed Web of Science ®Google Scholar
• Inomata M, Kado T, Okazawa S, et al. Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor. Anticancer Res. 2019;39(12):6887–6893. doi:10.21873/anticanres.13908
   PubMed Web of Science ®Google Scholar
• Leuchte K, Staib E, Thelen M, et al. Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma. Cancer Immunol Immunother. 2021;70(4):893–907. doi:10.1007/s00262-020-02734-1
   PubMed Web of Science ®Google Scholar
• Rochigneux P, Nault JC, Mallet F, et al. Dynamic of systemic immunity and its impact on tumor recurrence after radiofrequency ablation of hepatocellular carcinoma. Oncoimmunology. 2019;8(8):1615818. doi:10.1080/2162402x.2019.1615818
   PubMed Web of Science ®Google Scholar